Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUS-guided I-125 Seeds + Gem/nab-P in Metastatic Pancreatic Cancer
NCT05869474Recruiting
- Sponsor
- Changhai Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Changhai Hospital. Primary endpoint: Overall Survival at 48 months. Started Aug 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05869474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869474.